April 29 (Reuters) - Moleculin Biotech Inc MBRX.O:
MOLECULIN ANNOUNCES NEW PRE-CLINICAL DATA FOR ANNAMYCIN DEMONSTRATING MARKET EXPANSION POTENTIAL INCLUDING TREATMENT FOR PANCREATIC CANCER
Source text: ID:nGNX6GVSWC
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))